GLP-1 Obesity Care in Southeast Asia: How a Breakthrough Wave Reshapes Chronic Disease Demand

Across Asia-Pacific, multiple sources describe fast growth tied to improving healthcare access and the rise of metabolic disease. Grand View Research data cited in a 2026 press release states the Asia-Pacific GLP-1 receptor agonist market reached USD 5.47 billion in 2025 and is projected to grow to USD 16.95 billion by 2033, at a CAGR of 14%. In a separate forecast, Fortune Business Insights estimates the Asia-Pacific semaglutide market will reach USD 4.67 billion in 2026. Another market view from Precedence Research says Asia Pacific held a 22% share of the injectable peptides drugs market in 2025 and is expected to grow at the fastest CAGR of 11.5%, driven by expanding healthcare access and rising chronic disease prevalence across China, India, Japan, and Southeast Asia.

Singapore Shows What GLP-1 Obesity Care Can Look Like in Practice

Real-world outcomes from a metabolic health clinic program in Singapore show how GLP-1 care can be operationalized in a private, largely self-paid setting. The analysis covers patients enrolled in an mHealth counseling and GLP-1 receptor agonist-based intervention for at least 3 months, between March 30, 2022 and June 30, 2024, in Singapore (population 6.04 million). Participants had a mean age of 42.1 years and were 64.1% female. They were primarily East Asian (45.5%), European (26.8%), South Asian (13.3%), and Southeast Asian (10.3%). Most received semaglutide, with 86% on oral 14 mg. At 12 months, mean weight loss was 12.7% (95% CI: –14.0, –11.3), BMI fell by 4.1 points, and weight loss reached 14.7% at 18 months.

The Singapore program also reported changes that matter to broader chronic disease planning, not just weight alone. Systolic blood pressure decreased by 11.5 mmHg, body fat percentage by 8.8%, waist-to-hip ratio improved from 0.83 to 0.80, and HbA1c declined by 0.6%. Engagement signals were measurable: participants logged a median of 34.7 entries per month (IQR: 13.3–78.8), sent 3.9 messages per month (IQR: 1.3–7.8), and spent a median of 19.0 minutes per month on the app (IQR: 3.7–54.6). Greater app engagement was linked to 2.0–2.2% additional weight loss and up to 2.9 mmHg greater systolic BP drop. However, retention patterns varied: compared with East Asians, South Asians had lower odds of staying beyond 9 months (OR 0.56; 95% CI: 0.33, 0.94) and Southeast Asians also had lower odds (OR 0.38; 95% CI: 0.20, 0.70).

Even with strong clinical momentum, realized demand depends on access and persistence. IQVIA reports that, in obesity GLP-1 use, only 10% of patients persist with therapy after one year, with 90% of total demand lost due to payer friction, abandonment, and non-persistence. Diabetes-indicated GLP-1s perform better in that same analysis, with 24% retention at one year, but still show leakage. In the United States, IQVIA also reports GLP-1s accounted for 52% of all diabetes prescription volume by May 2025, up from 18% in 2020, illustrating how quickly prescribing can shift when coverage and disease framing align. For health leaders thinking about GLP-1 Obesity Care Southeast Asia, the lesson is practical. Outcomes and engagement can be strong, but sustainable chronic disease impact requires delivery models that reduce drop-off and better match how care is paid for.